摘要
目的分析小儿咳嗽变异性哮喘(CVA)的特点,评价布地奈德联合孟鲁司特钠治疗的预后效果。方法80例小儿咳嗽变异性哮喘患儿,随机分为对照组及观察组,每组40例。对照组患儿采取布地奈德治疗,观察组患儿采取布地奈德联合孟鲁司特钠治疗。比较两组患儿的临床疗效,治疗前后的肺功能指标[用力肺活量(FVC)、第1秒用力呼气容积(FEV1)]、炎症因子[肿瘤坏死因子-α(TNF-α)、白细胞介素-4(IL-4)]水平。结果观察组患儿的总有效率95.00%高于对照组的70.00%,差异具有统计学意义(P<0.05)。治疗前,两组患儿的FVC、FEV1、TNF-α、IL-4水平比较,差异无统计学意义(P>0.05);治疗后,观察组患儿的FVC(3.30±1.10)L、FEV1(2.50±0.50)L高于对照组的(2.50±0.80)、(2.02±0.50)L,TNF-α(0.53±0.10)μg/L、IL-4(56.20±8.80)ng/L低于对照组的(0.90±0.12)μg/L、(95.50±10.50)ng/L,差异具有统计学意义(P<0.05)。结论小儿咳嗽变异性哮喘患儿在布地奈德联合孟鲁司特钠的协同治疗下,能够有效提升治疗效果,减轻患儿的炎症因子水平,改善肺功能。
Objective To analyze the characteristics of cough variant asthma(CVA)in children,and evaluate the prognostic effect of budesonide combined with montelukast sodium.Methods A total of 80 children with cough variant asthma were randomly divided into control group and observation group,with 40 cases in each group.Children in the control group were treated with budesonide,and children in the observation group were treated with budesonide combined with montelukast sodium.Both groups were compared in terms of clinical efficacy,pulmonary function indexes[forced vital capacity(FVC),forced expiratory volume in one second(FEV1)],inflammatory factors[tumor necrosis factor-α(TNF-α),interleukin-4(IL-4)]levels before and after treatment.Results The total effective rate of the children in the observation group was 95.00%,which was higher than 70.00%in the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in the levels of FVC,FEV1,TNF-αand IL-4 between the two groups(P>0.05).After treatment,the FVC(3.30±1.10)L and FEV1(2.50±0.50)L of children in the observation group were higher than(2.50±0.80)and(2.02±0.50)L in the control group;the TNF-α(0.53±0.10)μg/L and IL-4(56.20±8.80)ng/L in the observation group were lower than(0.90±0.12)μg/L and(95.50±10.50)ng/L in the control group;the differences were statistically significant(P<0.05).Conclusion The synergistic treatment of budesonide and montelukast sodium can effectively improve the therapeutic effect of CVA in children,reduce the level of inflammatory factors in children,and improve their pulmonary function.
作者
杨红梅
YANG Hong-mei(Department of Pediatrics,Fengcheng Central Hospital,Dandong 118100,China)
出处
《中国现代药物应用》
2023年第2期133-135,共3页
Chinese Journal of Modern Drug Application
关键词
布地奈德
孟鲁司特钠
小儿咳嗽变异性哮喘
炎症因子水平
肺功能
治疗效果
Budesonide
Montelukast sodium
Cough variant asthma in children
Inflammatory factor levels
Pulmonary function
Therapeutic effect
